Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an update.
Lumos Diagnostics Holdings Ltd. has applied to the ASX for quotation of 31,098,017 new ordinary fully paid shares, with an issue date of April 9, 2026. The application indicates an expansion of the company’s quoted securities on the market, which may affect its capital structure and liquidity for existing and prospective shareholders.
The newly quoted securities arise from the exercise or conversion of existing options or other convertible instruments into ordinary shares. This move formalises the listing of these additional shares on the ASX and signals ongoing corporate activity that could influence trading dynamics and investor perception of Lumos Diagnostics’ growth trajectory.
The most recent analyst rating on (AU:LDX) stock is a Hold with a A$0.21 price target. To see the full list of analyst forecasts on Lumos Diagnostics Holdings Ltd. stock, see the AU:LDX Stock Forecast page.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a medical diagnostics company listed on the ASX under the code LDX. It focuses on developing and commercialising diagnostic technologies and products for healthcare markets, with its ordinary fully paid shares traded on the Australian Securities Exchange.
Average Trading Volume: 4,421,380
Technical Sentiment Signal: Buy
Current Market Cap: A$168.6M
For an in-depth examination of LDX stock, go to TipRanks’ Overview page.